JP Morgan Initiates Coverage On Arcus Biosciences with Overweight Rating, Announces Price Target of $41
JP Morgan analyst Priyanka Grover initiates coverage on Arcus Biosciences (NYSE:RCUS) with a Overweight rating and announces Price Target of $41.
Share
Why It Matters
A big bank analyst thinks Arcus Biosciences is a good company to watch. This means she believes the stock could do well, so it's worth paying attention to.
This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.
Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.